SiranBio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $59M

  • Investors
  • 10

SiranBio General Information

Description

Developer of innovative drugs designed for the nucleic acid therapy field. The company offers single-target and dual-target nucleic acid drug technology platforms and extrahepatic delivery platforms, and it has rapidly developed a pipeline of small nucleic acid drugs for intrahepatic and extrahepatic FIC and BIC, including antiviral, cardiovascular and metabolic diseases, autoimmunity, central nervous system, and other related diseases, thereby providing customers with reliable and innovative products.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 301, Building 1, Area A, Phase III Biomedical Industrial Park
  • Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Unit 301, Building 1, Area A, Phase III Biomedical Industrial Park
  • Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
  • Suzhou, 215000
  • China
+86 0512

SiranBio Timeline

2023202420252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SiranBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 03-Jul-2026 $59M Completed Generating Revenue
4. Early Stage VC 24-Nov-2025 Completed Generating Revenue
3. Early Stage VC 25-Aug-2025 Completed Generating Revenue
2. Early Stage VC 06-Mar-2024 Completed Generating Revenue
1. Seed Round 14-Jun-2022 Completed Startup
To view SiranBio’s complete valuation and funding history, request access »

SiranBio Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Huatai Zijin Investment Corporate Venture Capital Minority
IDG Capital Venture Capital Minority
SDIC Capital Management Growth/Expansion Minority
Sunshine Ronghui Capital Investment Management Corporate Venture Capital Minority
Suzhou Angel Fund of Funds Government Minority
You’re viewing 5 of 10 investors. Get the full list »

SiranBio FAQs

  • When was SiranBio founded?

    SiranBio was founded in 2022.

  • Where is SiranBio headquartered?

    SiranBio is headquartered in Suzhou, China.

  • What industry is SiranBio in?

    SiranBio’s primary industry is Drug Discovery.

  • Is SiranBio a private or public company?

    SiranBio is a Private company.

  • What is SiranBio’s current revenue?

    The current revenue for SiranBio is .

  • How much funding has SiranBio raised over time?

    SiranBio has raised $59M.

  • Who are SiranBio’s investors?

    Huatai Zijin Investment, IDG Capital, SDIC Capital Management, Sunshine Ronghui Capital Investment Management, and Suzhou Angel Fund of Funds are 5 of 10 investors who have invested in SiranBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process